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Abstract 
Background: Atenolol, a hydrophilic beta blocker, has been used as a model drug for studying passive permeability 
of biological membranes such as the blood–brain barrier (BBB) and the intestinal epithelium. However, the extent of 
S‑atenolol (the active enantiomer) distribution in brain has never been evaluated, at equilibrium, to confirm that no 
transporters are involved in its transport at the BBB.
Methods: To assess whether S‑atenolol, in fact, depicts the characteristics of a low passive permeable drug at the 
BBB, a microdialysis study was performed in rats to monitor the unbound concentrations of S‑atenolol in brain extra‑
cellular fluid (ECF) and plasma during and after intravenous infusion. A pharmacokinetic model was developed, based 
on the microdialysis data, to estimate the permeability clearance of S‑atenolol into and out of brain. In addition, the 
nonspecific binding of S‑atenolol in brain homogenate was evaluated using equilibrium dialysis.
Results: The steady‑state ratio of unbound S‑atenolol concentrations in brain ECF to that in plasma (i.e.,  Kp,uu,brain) was 
3.5% ± 0.4%, a value much less than unity. The unbound volume of distribution in brain  (Vu, brain) of S‑atenolol was 
also calculated as 0.69 ± 0.10 mL/g brain, indicating that S‑atenolol is evenly distributed within brain parenchyma. 
Lastly, equilibrium dialysis showed limited nonspecific binding of S‑atenolol in brain homogenate with an unbound 
fraction  (fu,brain) of 0.88 ± 0.07.
Conclusions: It is concluded, based on  Kp,uu,brain being much smaller than unity, that S‑atenolol is actively effluxed 
at the BBB, indicating the need to re‑consider S‑atenolol as a model drug for passive permeability studies of BBB trans‑
port or intestinal absorption.
Keywords: Atenolol, Blood–brain barrier, Microdialysis, Unbound equilibrium partition coefficient  (Kp,uu,brain), 
Unbound volume of distribution in brain  (Vu,brain), Passive permeability, Transporters, Pharmacokinetics, Lipophilicity
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Background
Atenolol is a selective beta receptor blocker for the treat-
ment of hypertension with the enantiomer S-atenolol 
responsible for the main active pharmacological effect 
[1–3]. For a long time, atenolol has been considered as 
a typical representative of a hydrophilic small molecule 
with low passive permeability and low paracellular dif-
fusion across intestinal membrane and blood–brain 
barrier (BBB). Thus, it has been used as a model drug in 
developing and evaluating in  vitro or in  situ models for 
intestinal absorption and CNS penetration [4–6].
Like the intestinal epithelium, the BBB is character-
ized by tight junctions formed between adjacent cerebral 
capillary endothelial cells. These restrict paracellular 
transport, a pathway important for ions and other small 
hydrophilic molecules, which thus have lower permeabil-
ity across the BBB and enterocytes. On the other hand, 
tight junctions have a limited effect on the BBB and intes-
tinal permeability for lipophilic molecules that mainly 
use the transcellular pathway [7].
There have been several in  vivo methods developed 
to assess the rate of drug transport across the BBB, 
including intravenous injection to measure the BBB 
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permeability surface area product, intra-arterial injec-
tion to measure the brain uptake index, as well as in situ 
brain perfusion to assess BBB permeability using well-
controlled perfusate [8–10]. From the above methods, if 
the samples are collected at very early time points, drug 
transport from brain back to blood is considered to be 
low and thus negligible, in which case the rate of initial 
brain uptake can be specifically studied. However, this 
includes possible influences of efflux transporters on 
the rate of brain uptake. Instead of assessing transport 
rate across the BBB, microdialysis can be used to evalu-
ate the rate as well as extent of drug transport by meas-
uring unbound drug concentrations in the extracellular 
fluid (ECF) of brain tissues over a longer duration. By 
modeling the microdialysis data with the information of 
unbound drug volume of distribution in brain  (Vu,brain) 
the permeability in both directions, influx clearance into 
brain  (CLin) and efflux clearance from brain  (CLout), can 
also be estimated [11].  CLin and  CLout values are deter-
mined by the contribution of both passive diffusion and 
active transport. Moreover,  CLout may be affected by 
metabolism and ECF bulk flow [12]. The ratio of  CLin 
over  CLout values, is equal to the unbound equilibrium 
partition coefficient,  Kp,uu,brain, which is defined as the 
ratio of unbound drug concentration in brain ECF to that 
in plasma at the steady state [13]. Even when steady state 
concentrations are not achieved, but with rate processes 
following first order kinetics (i.e. linear pharmacokinet-
ics),  Kp,uu,brain can be estimated using the ratio of area 
under curve of unbound drug concentration–time pro-
files  (AUCu) in brain ECF to  AUCu in plasma. It should 
be noted that the  Kp,uu,brain value reflects the extent of 
unbound drug concentration equilibration between brain 
and plasma, but not the rate with which a drug crosses 
the BBB [12]. Typically, BBB permeability is a measure of 
the rate of BBB transport of the drug. Compounds with 
lower lipophilicities tend to have lower BBB permeabil-
ity, only if passive transport governs the exchange of drug 
molecules across the BBB.
For a drug with only passive transport across the BBB, 
it holds that  CLin = CLout with respect to unbound drug, 
making  Kp,uu,brain equal to unity. In other words, at steady 
state, the unbound drug concentration in brain ECF is 
equal to that in plasma. Drugs with a low BBB perme-
ability just need more time to reach such equilibrium, but 
 Kp,uu,brain is independent of BBB permeability [12].
If atenolol were a typical drug of low passive BBB per-
meability, it would have equal  CLin and  CLout, leading 
to the following characteristics: (1) without any carrier-
mediated transport or being metabolized in brain, its 
 Kp,uu,brain value would be unity [12]; (2) as the net direc-
tion of mass transport for passive diffusion is only deter-
mined by unbound concentration gradient between the 
two sides of BBB, its unbound brain concentration would 
keep increasing when higher unbound concentrations 
are present in blood than in brain (i.e.  Cu,blood > Cu,brain) 
and  Cu,brain would start decreasing when  Cu,blood < Cu,brain. 
However, a previous microdialysis study of atenolol 
in rats showed a ratio of  AUCu in brain ECF to AUC in 
plasma of only 3.8 ±  0.6% after an intravenous 10  mg 
bolus dose. In addition, the peak of the  Cu,brain was at 
around 10  min, when the plasma concentration was 
much higher than  Cu,brain. Moreover, both unbound brain 
and plasma concentration–time profiles had the same 
half-lives [14]. This is not consistent with the expected 
profile described above for compounds with only passive 
permeability. Instead, the reported  Cu, brain-time profile of 
atenolol resembles that of compounds with active efflux, 
based on the simulations performed by Hammarlund-
Udenaes et al. [15].
If indeed atenolol has a very low  Kp,uu,brain due to it 
being a substrate of an efflux transporter, it has impor-
tant implications on the role of atenolol as a model drug 
for low passive permeability (i.e. low paracellular diffu-
sion without any carrier-mediated transport), and thus 
the conclusions from the related research of biological 
membrane barriers may need reevaluation. Therefore, 
the aim of this study was to investigate in-depth the 
in vivo net flux of S-atenolol BBB transport. To that end, 
a detailed microdialysis study was carried out to evaluate 
the  Kp,uu,brain of S-atenolol, and investigate its intra-brain 
distribution by assessing the  Vu,brain and the unbound 
drug fraction in brain homogenate  (fu,brain). Modeling and 
simulation were used to describe the properties of ateno-
lol from a rate and extent perspective.
Methods
Chemicals
S-(−)-atenolol and atenolol-D7 were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). Isoflurane was 
obtained from Baxter Medical AB (Kista, Sweden). 
Ringer’s solution was prepared to perfuse microdialy-
sis probes and comprised 145  mM NaCl, 0.6  mM KCl, 
1.0 mM  MgCl2, 1.2 mM  CaCl2, and 0.2 mM ascorbic acid 
in 2  mM phosphate buffer (pH 7.4). Normal saline was 
obtained from Braun Medical AB (Stockholm, Sweden), 
and water was purified using a Milli-Q system (Millipore, 
Bedford, MA, USA). Ammonium acetate and acetonitrile 
were purchased from Merck (Darmstadt, Germany). All 
other chemicals were of analytical grade.
Animals
Male Sprague–Dawley rats (250–310  g) were obtained 
from Taconic (Lille Skensved, Denmark). The animals 
were acclimated for 1  week before the experiment and 
housed in groups with 12-hour day-night cycles at 22 °C. 
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The microdialysis study was approved by the Animal Eth-
ics Committee of Uppsala University, Sweden (C328/10).
Microdialysis study
For the microdialysis study, vessel catheters and micro-
dialysis probes were implanted in rats as previously 
described [13, 16]. Briefly, the rats were anesthetized 
using 2.5% isoflurane and their body temperature were 
maintained at 37  °C using CMA/150 temperature con-
troller (CMA, Stockholm, Sweden) throughout the sur-
gery. Firstly, a catheter made from PE-50 fused with 
silicon tubing was implanted into the femoral vein for 
S-atenolol infusion, followed by the insertion of a PE-50 
catheter fused with PE-10 into the femoral artery for 
blood sampling. Secondly, an incision was made to 
insert a CMA/20 microdialysis probe (CMA, Stock-
holm, Sweden) with 10  mm flexible polyarylethersul-
phone (PAES) membrane into the right jugular vein for 
sampling unbound S-atenolol in plasma. Then, the head 
of the rat was fixed on a stereotaxic frame and a guide 
cannula was implanted into striatum with the coordi-
nates 0.8 mm anterior, 2.7 mm lateral to the bregma, and 
3.8 mm ventral to the surface of the skull. Dental cement 
was used to fix the guide cannula onto the skull with 
an anchor screw. The tubing of the vessel catheters and 
microdialysis probe were tunneled subcutaneously and 
fixed at the back of the neck. At the end of the surgery, 
the dummy inside the guide cannula was replaced by a 
CMA/12 microdialysis probe (CMA, Stockholm, Swe-
den) with a 3  mm PAES membrane (20  kDa cutoff) for 
sampling S-atenolol in brain ECF. The rats were allowed 
to recover for 1  day before the microdialysis study and 
to move freely in a CMA 120 system with free access to 
food and water.
As shown in Fig.  1, the rats were divided into two 
groups with different dosing regimens. The infusion 
solution had a drug concentration of 5 mg/mL. Group 1 
(n = 9) received S-atenolol starting with a fast infusion at 
0.4 mg/min/kg for 15 min followed by a slow infusion of 
0.182 mg/min/kg for 165 min using a Harvard 22 pump 
(Harvard Apparatus Inc., Holliston, MA, USA) in order 
to rapidly achieve steady state concentrations in plasma. 
Samples were collected for another 3 h after the end of 
drug infusion in four rats (Group 1a). The rats in Group 
1b (n = 5) were decapitated at the end of the infusion to 
harvest the brains in order to measure the total S-ateno-
lol amount in brain tissue. In Group 2 (n = 4), S-atenolol 
was given as a single constant infusion for 3 h at a rate of 
0.167 mg/min/kg, and continuing sampling for 3 h there-
after. In all rats, the microdialysis perfusion was started 
at the beginning of the stabilization period, 90 min before 
S-atenolol dosing. Deuterated atenolol, atenolol-D7, was 
used to measure the relative recovery across the micro-
dialysis probes throughout the study, using retrodialysis 
by the atenolol-D7 as a calibrator [17, 18]. Atenolol-D7 
was added to the Ringer’s solution at 50 ng/mL for brain 
probe and at 200  ng/mL for plasma probe, which were 
perfused through the microdialysis probes using a CMA 
400 pump (CMA, Solna, Sweden) at a flow rate of 1 µL/
min. The dialysates were collected every 15 min by a frac-
tion collector (CMA 142, Solna, Sweden) until the end of 
experiment. For the animals with their drug elimination 
Fig. 1 Design of the microdialysis study of S‑atenolol showing the time aspects of i.v. infusion (red and pink bars), microdialysis sampling (blue 
bars), plasma sampling (black arrows), and brain tissue sampling (red arrow)
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phase monitored, 100  µL of blood was drawn from the 
femoral artery pre-dose and at 5, 10, 90, 150, 185, 200, 
240, and 360  min after the start of S-atenolol infusion. 
For the rats decapitated at the end of drug infusion, the 
blood was collected pre-dose and at 5, 10, 30, 60, 90, 120, 
150, and 175 min. All blood samples were centrifuged at 
7200g for 5  min to obtain plasma, which together with 
brain and microdialysis samples were frozen at − 20  °C 
until analysis.
Equilibrium dialysis study
The  fu,brain at three drug concentrations was measured 
in vitro using equilibrium dialysis of brain homogenate. 
Briefly, Sprague–Dawley rats were decapitated under 
isoflurane anesthesia and the brains were collected and 
homogenized in four volumes of 180  mM phosphate 
buffer. After being spiked with 132.5, 265, and 1325 ng/
mL S-atenolol (corresponding to 0.5, 1, and 5  µM), 
150  µL of the blank homogenate was dialyzed against 
PBS pH 7.4 for 6 h using a Pierce Rapid Equilibrium Dial-
ysis Device (RED) (Thermo Scientific, Rockford, IL, USA) 
(n =  5 at each concentration) with a shaking speed of 
200 rpm at 37 °C (MaxQ4450, Thermo Fisher Scientific, 
Nino Lab, Sweden). Samples were collected from both 
buffer and homogenate sides at the end of the incubation 
period of 6 h. The stability of S-atenolol in brain homoge-
nate was evaluated by incubating homogenate containing 
the drug at the three concentrations and collecting sam-
ples before and after the incubation. In order to obtain 
the same matrix for all samples in the chemical assay, 
the same volume of buffer was added to brain homoge-
nate samples and vice versa. All samples were stored at 
− 20 °C until assay. The unbound fraction of S-atenolol in 
diluted brain homogenate  (fu,hD) was calculated from the 
buffer/homogenate concentration ratio as:
The unbound fraction of S-atenolol in brain was cal-
culated according to Eq.  2 after correction for the dilu-
tion factor D associated with the preparation of brain 
homogenate (D = 5 in this study):
Chemical analysis
Liquid chromatography coupled with tandem mass 
spectrometry (LC–MS/MS) was used to determine 
the concentrations of S-atenolol and atenolol-D7 in 
the microdialysis samples. Five microliters of the brain 
microdialysis samples were directly injected into the 












high drug concentrations were diluted by adding 150 µL 
Ringer’s solution before analysis. After thawing to room 
temperature, the plasma samples were precipitated at 
a ratio of 1:3 with acetonitrile containing 500  ng/mL 
atenolol-D7 as internal standard. Following vortex mix-
ing and centrifugation for 3  min at 7200g, 25  µL of the 
supernatant was further diluted by mixing it with 1 mL 
of 5  mM ammonium acetate solution and then inject-
ing 10 µL of the mixture into the LC–MS/MS. The brain 
samples were homogenized with a tissue-saline ratio of 
1:4 (w/v), prepared as described above. Then 150  µL of 
the homogenate was mixed with 150 µL of 50 ng/mL ate-
nolol-D7 aqueous solution, and further precipitated with 
150 µL acetonitrile. After 3 min centrifugation at 7200g, 
the supernatant was diluted tenfold with 5  mM ammo-
nium acetate, injecting 50 µL. The homogenate samples 
from equilibrium dialysis were prepared with the same 
procedures as above. Standard curves were generated 
for all types of biological matrix (i.e., 0.5–500 ng/mL for 
dialysate; 50–10,000  ng/mL for plasma; 25–1000  ng/g 
brain for brain tissues from microdialysis study; 6.25–
875 ng/mL for brain homogenate samples from equilib-
rium dialysis study) and quality control samples at low, 
medium and high concentrations were analyzed along 
with the samples for measurement validation. The coeffi-
cients of determination  (r2) were ≥ 0.994 for all standard 
curves.
The LC–MS/MS system consisted of two Shimadzu 
LC-10ADvp pumps (Shimadzu, Kyoto, Japan), a SIL-
HTc autosampler (Shimadzu, Kyoto, Japan), and a Quat-
tro Ultima mass spectrometer (Waters, Milford, MA, 
USA). A HyPurity C18 column (50  ×  4.6  mm, 3  µm 
particle size), equipped with a HyPurity C18 guard col-
umn (10 × 4.0 mm, 3 µm particle size, Thermo Scientific 
Hypersil-Keystone, PA, USA), was used for chroma-
tographic separation with a gradient elution involving 
mobile phase A (5 mM ammonium acetate in water) and 
mobile phase B (90:10 v/v acetonitrile:water). The flow 
rate was set to 0.8 mL/min, which was split to 0.3 mL/
min before entering the mass spectrometer, where posi-
tive electrospray ionization (ESI  +) was applied. The 
transition mode was m/z 266.9 → 145 for S-atenolol and 
m/z 273.8 →  145 for atenolol-D7. All chromatographs 
were acquired and analyzed using Masslynx 4.0 (Waters, 
Milford, MA, USA).
Calculations and pharmacokinetic data analysis
The relative recovery of S-atenolol for each microdialysis 
probe was evaluated using retrodialysis with atenolol-D7 
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where  Cin,ATD7 and  Cout,ATD7 are the concentrations 
of atenolol-D7 in perfusate and dialysate, respectively 
[18]. The relative recovery simultaneously determined 
by the retrodialysis of atenolol-D7 was 6.94 ± 0.67% for 
the microdialysis probes in brain and 50.1  ±  1.9% for 
the probes in blood without any time-dependence. The 
unbound concentration of S-atenolol in brain ECF and 
plasma was calculated by dividing the measured S-ateno-
lol concentration in dialysate by the relative recovery.
The  Kp,uu,brain was calculated to characterize the extent 
of S-atenolol equilibration across the BBB as:
where  Cu,ss,brainECF and  Cu,ss,plasma are the unbound drug 
concentrations in brain ECF and plasma at the steady 
state, respectively.
The half-lives in brain ECF and plasma,  t1/2,brainECF and 
 t1/2,plasma, were calculated based on the corresponding 
middle time points of microdialysis collection intervals of 
the elimination phase:
where λz is the terminal rate constant obtained from 
the last seven observations. The half-lives of unbound 
S-atenolol in brain ECF and plasma were compared using 
paired t test.
A pharmacokinetic model was developed using non-
linear mixed effect modeling (NONMEM, version 7.3.0, 
ICON Development Solutions, Ellicott City, MD, US) 
to describe the rate of S-atenolol transport across the 
BBB via  CLin and  CLout. The method of first-order con-
ditional estimation with interaction (FOCEI) was used 
throughout the modeling procedure. The inter-individ-
ual variability was investigated for all pharmacokinetic 
parameters during the model development using an 
exponential model:
where  Pi is the value of the parameter for the i-th individ-
ual, while  Ppop is the typical value of the parameter in the 
population. The inter-individual variability was described 
by η, which was assumed to follow a normal distribu-
tion with a mean at 0 and standard deviation ω. In addi-
tion, different error models (proportional, additive, and 
slope-intercept error models) were explored to evaluate 
the residual variability, i.e. the difference between pre-
dicted and observed concentrations, for each type of 
observations.
The model selection was based on the objective func-
tion value (OFV), model parameter precision and graphi-








between nested models. Specifically, the difference in 
OFV between two nested models asymptotically follows 
χ2 distribution, and a drop in OFV of ≥  3.84 indicates 
the superiority of the model for one-parameter difference 
with p ≤ 0.05. The parameter precision was described by 
relative standard error, RSE  %, which was calculated as 
the standard error (S.E.) divided by the parameter esti-
mate. The graphical analyses were performed using PsN 
(version 4.4.0, Uppsala University, Uppsala, Sweden) and 
Xpose 4 (version 4.5.3, Uppsala University, Uppsala, Swe-
den) together with R (version 3.3.1, R Foundation for Sta-
tistical Computing, Vienna, Austria).
The previously developed integrated plasma-brain 
pharmacokinetic model for oxymorphone, oxycodone, 
and DAMGO was used in this study, with modifica-
tion based on the data from the microdialysis study of 
S-atenolol [13, 19, 20]. All observed data of S-atenolol 
were included in the model comprising total plasma 
concentration in arterial sampling, unbound concentra-
tion in venous plasma from microdialysis sampling in 
jugular vein, and unbound concentration in brain ECF 
from microdialysis sampling in right striatum (Fig.  2). 
The model also took into account the relative recovery by 
including the concentrations of the calibrator atenolol-
D7 in dialysate from both probes.
The model development started by building a plasma 
PK model, followed by adding the other compartments 
in steps. The parameters in the final model were esti-
mated simultaneously based on all data. In the model, 
the central compartment was divided into two com-
partments, an arterial compartment for plasma con-
centration and a venous compartment for microdialysis 
sampling. The two compartments were assumed to have 
equal unbound volume of distribution, that is, VA = VV. 
The transport of S-atenolol across the BBB was param-
eterized by  CLin and  Kp,uu,brain, which were assessed 
according to:
where  kin and  kout denote the rate constants between the 
arterial compartment and the brain compartment.  Vu,brain 
(mL/g brain) reflects the drug distribution within brain 
parenchyma since it describes the relationship between 
the total drug amount in brain and the unbound drug 
concentration in brain ECF:




(9)CLout = kout · Vu,brain
(10)Vu,brain =
Abrain − Cp × Vbl × Rbl−p
Cu,ECF
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where  Abrain is the measured drug amount in brain 
and  Cp is the plasma concentration at the end of infu-
sion. The volume of vascular space in rat brain  (Vbl) is 
0.014 mL/g brain [21], and the blood-to-plasma concen-
tration ratio of atenolol  (Rbl-p) is reported as 1.07 [22].
In order to illustrate the difference between efflux-
transported drug and a drug with only passive diffu-
sion across the BBB, simulations were performed for the 
cases: (1)  CLin = CLout and (2)  CLin < CLout with a con-
stant i.v. infusion of 0.167 mg/min/kg (assuming a 280-g 
rat). The PK parameters were set as the typical values 
obtained from S-atenolol modeling.
All data are expressed as mean ±  SEM in this report 
and GraphPad Prism v5.04 (GraphPad Software Inc., San 
Diego, CA) was used for statistical analysis and plots.
Results
Microdialysis study
In Group 1, the unbound S-atenolol concentration in 
plasma increased quickly during the 15-min fast infusion 
and was maintained at steady state  (Cu,ss,plasma) during 
the following 165  min slow infusion (Fig.  3a). The con-
centrations in plasma were comparable to the unbound 
S-atenolol concentration in plasma, indicating little to 
no binding of drug in plasma  (fu,p approaches 1). The 
steady state unbound concentration of S-atenolol in 
brain ECF was also quickly achieved and the concentra-
tion–time profile during elimination phase exhibited a 
similar shape to that in plasma. However, the brain ECF 
concentrations were much lower than in plasma through-
out the whole experiment. The unbound S-atenolol 
steady-state concentration in plasma calculated from 90 
to 180 min was 4429 ± 94 ng/mL, nearly 30-fold higher 
than in brain ECF (158  ±  20  ng/mL). The concentra-
tion–time profile of atenolol in Group 2 for the 3 h con-
stant i.v. infusion followed a similar pattern (Fig. 3b). The 
unbound S-atenolol level gradually increased during the 
infusion in plasma and brain ECF to 4127 ± 103 ng/mL 
and 256 ± 41 ng/mL, respectively, at the last time point 
before the infusion ended.
Fig. 2 Schematic illustration describing pharmacokinetics and brain distribution of S‑atenolol, and transformation of the microdialysis data by 
evaluating the probe recoveries. Solid arrows show mass transport between compartments (squares). Dashed arrows represent the transformations 
and corrections from observed dialysate data (ovals) to the unbound drug concentration in brain and plasma. Relative recoveries (REC), systemic 
total clearance (CL), clearance between arterial and peripheral compartments (Q), clearance between arterial and venous compartments  (QAV), 
volume of distribution of the arterial compartment  (VA), volume of distribution of the venous compartment (Vv), volume of distribution of the 
peripheral compartment  (V2), unbound fraction in plasma  (fu,p), influx clearance into brain  (CLin), efflux clearance out of brain  (CLout), and unbound 
volume of distribution in brain  (Vu,brain)
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There was a rapid exchange and equilibration of S-ate-
nolol across the BBB in spite of its low passive perme-
ability. For both groups during the elimination phase, 
brain ECF concentrations decreased at the same rate 
as in plasma, which was confirmed by similar termi-
nal half-lives in brain ECF and plasma (82 ±  7  min vs 
85 ±  10  min, p =  0.325, paired t-test). In addition, the 
unbound brain to plasma ratio with time was stable 
both during the infusion period and during the elimi-
nation phase (Fig.  4). The  Kp,uu,brain of S-atenolol was 
3.55% ± 0.40% during 90–180 min.
The  Vu,brain of S-atenolol was 0.686 ± 0.104 mL/g brain 
calculated from Eq. 10, which was not significantly differ-
ent from the brain total water volume (0.8  mL/g brain) 
(p = 0.137). This suggested an even distribution of ateno-
lol in brain with nonsignificant binding to brain paren-
chymal tissue and similar drug concentration in brain 
ECF and intracellular fluid (ICF) [12].
Equilibrium dialysis study
From the equilibrium dialysis of brain homogenates, it 
was found that the  fu,brain of S-atenolol was 0.74 ± 0.04, 
0.80 ± 0.04, and 1.09 ± 0.15 at the S-atenolol incubation 
concentrations of 0.5, 1.0, and 5.0 µM, respectively. There 
was no significant difference among the three S-atenolol 
levels with p =  0.0833 from one-way ANOVA analysis, 
suggesting that the nonspecific binding of S-atenolol in 
brain homogenate was independent of the incubation 
concentration. The average  fu,brain from all the three con-
centration groups was 0.875 ± 0.067, comparable with a 
previously reported value of 0.90 ± 0.052 [23], indicating 
very limited binding in brain homogenate, in line with 
the  Vu,brain estimates presented above. S-atenolol was 
very stable in brain homogenate with zero degradation 
(100 ± 1% recovery) during the 6 h incubation at 37 °C.
Pharmacokinetic modeling
To be able to calculate the BBB clearance values, and to 
better understand the kinetics of S-atenolol transport at 
the BBB, a pharmacokinetic model including a brain com-
partment was developed based on the microdialysis data. 
The individual plots in Fig. 5 show observations, individ-
ual predictions and population predictions of S-atenolol 
in plasma, blood dialysate, and brain dialysate. A notice-
able discrepancy between population and individual pro-
files was observed for some individuals (e.g. ID11 in brain 
dialysate), which may explain the large inter-individual 
variation for some parameters (Table  1). Nevertheless, 
the model is appropriate for describing S-atenolol dis-
tribution in plasma and brain, given the close median 
lines of real data and model-based simulation data in the 
Fig. 3 Individual concentration–time profiles of unbound S‑atenolol 
in plasma (solid triangles and line) and brain (solid circles and lines) as 
well as total S‑atenolol in plasma (open triangles and dashed lines) for 
(a) Group 1a and b (n = 9) with 15‑min fast i.v. infusion followed by 
165‑min slow i.v. infusion, and (b) Group 2 (n = 4) with constant slow 
i.v. infusion for 180 min. For two rats, the  Cu,brain data after 240 min are 
missing due to an LC–MS/MS malfunction during the analysis
Fig. 4 The ratio of unbound S‑atenolol in rat brain ECF to that in 
plasma  (Cu,brain/Cu,plasma) versus time for Group 1 (solid circles and 
lines) with 15‑min fast i.v. infusion followed by 165‑min slow i.v. 
infusion (n = 9) and for Group 2 (open circles and dashed lines) with 
180‑min constant i.v. infusion. The unbound partition coefficient 
 (Kp,uu,brain) was calculated during steady state (between 90 and 
180 min) for Group 1
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visual predictive check based on 200 simulations (Fig. 6). 
The typical values of relative recoveries estimated from 
the model that included atenolol-D7 concentrations 
in dialysates are comparable to the values calculated 
directly from Eq. 1, and the model-estimated  Kp,uu,brain of 
4.00% is also comparable to the value of 3.55% from Eq. 4. 
Fig. 5 Individual plots of the concentrations of S‑atenolol in plasma (a, d), blood dialysate (b, e), and brain dialysate (c, f) for Group 1 with 15‑min 
fast i.v. infusion followed by 165‑min slow i.v. infusion (a–c) and Group 2 with constant i.v. infusion for 180 min (d–f). Plots show observations (DV, 
solid circles), individual predictions (IPRED, solid lines), and population predictions (PRED, dash lines) from the model for each animal
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 CLin is estimated as 17.0 µL/min/g brain, and the result-
ant  CLout is 425 µL/min/g brain based on the definition of 
 Kp,uu,brain, as the ratio of  CLin to  CLout.
To illustrate the unbound concentration profile for a 
compound with only passive diffusion across the BBB, 
simulation was performed by assuming  CLout = CLin (17 
µL/min/g brain) with a 12-h i.v. infusion (Fig. 7a). In this 
case, the unbound drug concentration is equal in plasma 
and brain at the steady state. Also, brain concentration 
decreased at a slower rate than the plasma concentra-
tion immediately after the infusion termination. On the 
other hand, a simulation was performed using the  CLin 
and  CLout values (17 and 425  µL/min/g brain, respec-
tively) as estimated from the model of S-atenolol for the 
case of  CLin < CLout and as a result there is a considerable 
difference between  Cu,brain and  Cu,plasma (Fig.  7b) during 
and after the drug infusion. The simulation was also per-
formed based on the permeability surface area product of 
sucrose across the BBB (0.3 µL/min/g brain) [24]. Sucrose 
is a well-known marker for low intrinsic permeability 
without any active transport (Fig. 7c). Due to the lack of 
pharmacokinetic information of sucrose as well as our 
focus on the impact of BBB transport  (CLin and  CLout), the 
model structure and the other parameter estimates used 
for sucrose simulation were the same as those for S-aten-
olol. The bulk flow was not considered in the simulation 
as no study has been found to quantify its impact on drug 
elimination from brain ECF. Compared to the scenario of 
 CLin = CLout = 17 µL/min/g brain (Fig. 7a), the unbound 
brain concentration of sucrose in Fig. 7c takes much longer 
time to achieve 90% of steady state (3.7 days vs. 4 h) and 
has much longer half life during the elimination phase.
Discussion
Beta blockers exhibit highly variable lipophilicity and 
accordingly diverse pharmacokinetic properties [25], 
catching the attention of scientists who study drug per-
meability across biological barriers. Therefore, the hydro-
philic and lipophilic extremes in the beta blocker class, 
respectively, atenolol (logP of 0.23) and propranolol (logP 
of 3.65) have been used to study the relationship between 
lipophilicity and permeability in intestinal absorption 
and BBB penetration [25–27]. In addition, substantial 
efforts have been made to develop a variety of models 
to study and predict drug permeability, e.g. the in  vitro 
Caco-2 cell model for intestinal absorption and in  vitro 
brain capillary endothelial cell models for BBB trans-
port. To evaluate and characterize these models, ateno-
lol and propranolol are commonly used as model drugs 
for studying hydrophilic and lipophilic passive diffusion, 
respectively [5, 28, 29]. In addition to passive diffusion, 
carrier-mediated transport also plays a critical role in 
drug transport across biological barriers [30, 31]. Due 
to its importance, the function of transporters is usu-
ally evaluated by studying drug permeability across bio-
logical membranes in various in vivo, in situ, and in vitro 
Table 1 Parameter estimates of the S-atenolol pharmacokinetic model in rats
RSE relative standard error; IIV Inter-individual variation expressed as coefficient of variation; REC relative recoveries; CL systemic total clearance; V1 volume of 
distribution of total arterial and venous compartments; Q clearance between arterial and peripheral compartments; V2 volume of distribution of the peripheral 
compartment; fu,p unbound fraction in plasma; QAV clearance between arterial and venous compartments; Clin influx clearance into brain; Kp,uu,brain unbound partition 
coefficient in brain; Vu,brain unbound volume of distribution in brain; σ variances of the proportional or additive residual errors
Parameter Unit Estimate RSE (%) IIV (%) RSE IIV (%)
RECblood % 49.9 3.5 12.2 24.8
RECbrain % 6.73 9.5 27.9 17.2
CL mL/min 10.2 2.4 7.5 16.9
V1 mL 215 10.8 30.3 28.4
Q mL/min 5.56 8.9
V2 mL 402 4.8
fu,p 1.0 Fixed
QAV mL/min 15.4 9.2
CLin µL/min/gbrain 17.0 48.8 134.2 27.5
Kp,uu,brain 0.040 11.3 35.5 18.0
Vu,brain mL/g brain 0.686 Fixed
σproportional,RECbrain 0.028 9.4




σadditive,brain ng/mL 0.22 20.2
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models. In this context, atenolol is still used as a model 
drug for low passive/paracellular diffusion in permeabil-
ity-related studies without further systematic assessment 
of the possibility of it being a transporter substrate.
The current study monitored, for the first time, the 
unbound concentration of S-atenolol in brain ECF dur-
ing steady state and estimated its  Kp,uu,brain to assess 
whether it is likely that any transporter is participating 
in the atenolol transport across the BBB. If atenolol is a 
hydrophilic drug without any involvement of transport-
ers, it should have the profile of passive diffusion as in 
Fig. 7a with equal unbound concentration in plasma and 
brain at steady state. However, the present microdialysis 
study showed a profile with the S-atenolol  Kp,uu,brain much 
lower than unity (3.55 ± 0.40%), measured at steady state. 
The  Cu,brain/Cu,plasma was stable during both the steady 
Fig. 6 Visual predictive check for the final pharmacokinetic model 
based on 200 simulations for S‑atenolol concentrations in blood 
dialysate (a) and in brain dialysate (b). The pharmacokinetic model 
involves the transformation of microdialysis data by evaluating probe 
recoveries, and thus the observed data for the model are the uncor‑
rected drug concentrations in dialysate. Blue circles: observed data; 
red lines: median and 5th and 95th percentiles for observed data; 
black dashed line: median line of simulated data; green area: 95% 
confidence interval for the median simulated data
Fig. 7 Simulation of unbound S‑atenolol concentrations in arterial 
plasma (solid line) and in brain ECF (dashed line) for the sce‑
narios of a  CLin = CLout = 17 µL/min/g brain, b  CLin < CLout, and 
c  CLin = CLout = 0.3 µL/min/g brain (i.e. permeability surface area 
product of sucrose) with an i.v. infusion of 0.167 mg/min/kg
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state and the elimination phases (Fig. 4), and corresponds 
to the AUC ratio of brain ECF to plasma from a previ-
ous microdialysis study after an intravenous bolus dose 
(3.8  ±  0.6%) [14]. The lower-than-unity  Kp,uu,brain sug-
gests that efflux transporters are involved in the atenolol 
transport at the BBB, leading to a higher  CLout than  CLin. 
From the modeling approach, the  CLin value of atenolol in 
rats was 17.0 µL/min/g brain (Table 1), much lower than 
the  CLout of 425 µL/min/g brain (calculated according to 
Eq.   8). It should be noted that brain ECF bulk flow and 
metabolism may also contribute to discrepancies between 
 CLin and  CLout [12]. However, atenolol was found to be 
very stable in brain homogenate, thereby concluding that 
metabolism is not important. The relatively low bulk flow 
reported in rats of 0.1–0.3 µL/min/g brain [32, 33] is also 
of minor importance considering the estimation of  CLout 
to be 425  µL/min/g brain. The inter-individual variation 
was high with 134%, which was probably due to its low 
permeability into brain and the resultant low precision. 
Avdeef et al. measured atenolol  Kin (unidirectional trans-
fer constant into brain) under different pH values and 
concentrations, using the technique of in  situ rat brain 
perfusion [34]. The  Kin, which is similar to  CLin for com-
pounds with low permeability, was 1.8 µL/min/g brain for 
atenolol at 61.7 µM and pH 7.4, which is nearly 10% of the 
 CLin estimated from the model in the current study based 
on in  vivo data. However, their study also showed high 
inter-individual variation in  Kin with coefficient of vari-
ation (CV) ranging from 33.3% up to 1540% among the 
dosing groups. In another study published by Agon et al., 
positron emission tomography (PET) was used to monitor 
the brain uptake of atenolol in dogs after an i.v. bolus dose 
of 1.25 or 0.125 mg/kg [35]. By modeling the PET data,  Kin 
was estimated ranging from 0.7 to 1.5 µL/min/g brain and 
the rate constant out of brain  (kout) ranged from 0.0070 to 
0.0151/min. Because of a lack of dog  Vu,brain information, 
 CLout cannot be extracted from this PET study. However, 
it should be noted that instead of decreasing with blood 
concentration, the total drug concentration in dog brain 
remained at a stable level during the 90  min following 
the bolus dose. Given the low  fu,brain of atenolol due to its 
hydrophilic property, the difference in the profile of aten-
olol brain concentration between rats and dogs suggests a 
species difference in the BBB transport of atenolol.
By correcting for the surface area of endothelial cells 
in brain (100 cm2/g brain) [12], S-atenolol  CLin and  Clout 
estimated from the model correspond to 2.83 × 10−6 and 
70.8 × 10−6 cm/s of permeability coefficients into and out 
of rat brain, respectively. The permeability into brain was 
comparable to the  Papp value (apparent in vitro transcel-
lular permeability coefficient) assessed from an in  vitro 
BBB model using primary rat brain endothelial cells, per-
icytes, and astrocytes (2.49 × 10−6 cm/s) [5]. Compared 
to the above model, the  Papp values from in  vitro BBB 
models composed of only brain microvessel endothe-
lial cells were higher with 48.5 ×  10−6 cm/s for bovine 
(BBMEC) and 9.78  ×  10−6 cm/s for human (hBMEC) 
[36, 37]. The reported  Papp values from other in vitro cell 
models bearing tight junctions for both A–B and B–A 
directions were in the range of 0.18 × 10−6 − 11 × 10−6 
cm/s for Caco-2 cells and 0.13 × 10−6 − 0.8 × 10−6 cm/s 
for MDCKII (Madin-Darby canine kidney II cells) [37–
40]. Although showing large inter-laboratory variation, 
these values and ranges are lower than the out-of-brain 
permeability estimated in the current study (70.8 × 10−6 
cm/s), also suggesting the involvement of transporters 
in removing atenolol from the brain. Compared to the 
penetration permeability into the brain, atenolol exhib-
ited higher intestinal absorption permeability based on 
in situ intestinal perfusion (5.5 × 10−6 cm/s for rats and 
15 × 10−6 cm/s for human) [4, 41], which may be due to 
different characteristics of tight junctions and/or expres-
sion/function of related transporters.
Although being the most hydrophilic beta blocker, ate-
nolol shows a much higher  CLin than sucrose (17.0 vs. 
0.3  µL/min/g brain) [24]. Thus, the unbound profile of 
sucrose brain concentration was simulated to illustrate the 
unbound brain concentration–time profile of low intrin-
sic permeability (i.e. due to physicochemical property). As 
shown in Fig. 7c with  CLin and  CLout being the same and 
as low as 0.3 µL/min/g brain, the unbound brain concen-
tration increases very slowly taking approximately 3.7 days 
to achieve 90% steady state. The ratio of  Cu,brain to  Cu,blood 
is only 25% at 12  h, indicating the very long time that 
would be needed to reach equal concentrations for a com-
pound with such low intrinsic BBB permeability, (which 
therefore, in practice, is never measured at true equilib-
rium time points) and also showing a slower decline in 
unbound brain concentrations relative to unbound blood 
concentrations. Unlike the results of sucrose with low 
intrinsic permeability, the simulation of atenolol in Fig. 7b 
showed lower unbound concentration in brain than in 
blood at steady state, indicating the involvement of efflux 
transporter(s) in decreasing atenolol’s  Kp,uu,brain value. In 
summary, the atenolol delivery to the brain is limited by 
the extent but not the rate of BBB transport.
In addition to  Kp,uu,brain that is related to drug transport 
at the BBB,  fu,brain and  Vu,brain are important measures to 
understand drug distribution within the brain, describ-
ing the intra-brain distribution [12]. Drug  fu,brain describes 
nonspecific binding within brain tissue while  Vu,brain also 
describes intracellular distribution due to other reasons 
like transporters at some brain cell membranes. Similar 
to the nonspecific protein binding in plasma, hydrophilic 
drugs generally have low binding in brain homogenate 
[42]. From the equilibrium dialysis, atenolol had an  fu,brain 
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of 0.875 ±  0.067. In contrast, propranolol has extensive 
nonspecific binding in brain homogenate with an  fu,brain 
of 0.029 [23]. If drug is evenly distributed within the brain 
parenchymal fluid,  Vu,brain is close to the water volume 
of brain (0.8 mL/g brain). If drug is mainly is distributed 
inside brain cells or bound to brain tissues,  Vu,brain tends to 
be larger than 0.8 mL/g brain [12]. The  Vu,brain of S-ateno-
lol estimated from microdialysis and whole brain measure-
ments was 0.686 ± 0.104 mL/g brain, indicating no effects 
of transporters at the brain cells on the drug intra-brain 
distribution, or that there are transporters with counter-
active functions transporting the drug in both the inward 
and outward directions at the same clearances across brain 
cell membrane. The latter is however much less likely.
It should be noted that it is the unbound, free drug 
rather than the bound drug that directly interacts with 
pharmacological targets. As a result, unbound drug con-
centration is more relevant to drug therapeutic effect 
instead of total drug in brain. In addition, the unbound 
drug concentration in brain ECF rather than total concen-
tration of drug in brain tissue is more relevant in under-
standing drug transport across BBB because the total 
concentration of drug is confounded by ECF-ICF and/
or nonspecific binding equilibration (as characterized 
by  Vu,brain and  fu,brain). The conclusion about BBB trans-
port based on total drug concentrations in brain could 
therefore be misleading [43]. Thus, the  Kp,uu,brain based 
on unbound concentration in plasma and brain ECF at 
steady state is a more clinically relevant measure to quan-
tify drug transport at the BBB than rate measurements.
Our results suggest that some transporters actively 
eliminate atenolol from the brain, however no reports 
have been found to relate any possible BBB transporters 
with atenolol efflux. However, it was reported that fruit 
juices reduced the intestinal absorption of atenolol. The 
 Cmax and AUC were decreased by 49% and 40%, respec-
tively, by orange juice, and 68% and 81%, respectively, by 
apple juice, based on pharmacokinetic studies in human 
subjects [44, 45]. There is some controversy in the litera-
ture about the transporters responsible for the interac-
tion between atenolol and fruit juices. The organic anion 
transporting polypeptide 1A2 (OATP1A2) is suggested to 
be responsible of the atenolol uptake in the OATP1A2-
expressed X. laevis oocytes [46]. However, another study 
by Mimura et al. suggested that organic cation transporter 
1 (OCT1) rather than OATP probably contributes to the 
interaction between atenolol and flavonoids in fruit juices 
[47]. It was also reported that hOCT2 at the basolateral 
membrane of kidney tubules lead to renal active secre-
tion of atenolol [48]. Furthermore, the study performed 
by Yin et al. suggested that atenolol is also a substrate of 
multidrug and toxin extrusion proteins (hMATE-1 and 
hMATE2-K) located at the apical membrane of renal 
tubule, thus contributing to the elimination of atenolol 
from blood to urine together with OCT2 [49]. Among 
these possible transporters for atenolol, only OATP has 
been found expressed at the BBB with bidirectional trans-
port [50, 51]. OCT2 was also found to be expressed at the 
apical membrane of the blood-choroid plexus interface 
(i.e., CSF-facing), which may be relevant for efflux trans-
port of substrates from cerebrospinal fluid to blood [52].
In addition to the solute carrier family (SLC), sev-
eral members belonging to the ATP-binding cassette 
(ABC) transporter family are well known efflux trans-
porters at the BBB with a wide range of substances, 
including P-glycoprotein (Pgp), multidrug resistance 
protein (MRP), and breast cancer resistance protein 
(BCRP) [53]. Studies are limited in evaluating the poten-
tial of atenolol as a substrate of MRP and BCRP, while 
controversial results have been reported for the role 
of brain and intestinal Pgp on atenolol efflux. Kallem 
et al. reported that coadministration of elacridar, a Pgp 
inhibitor, did not significantly change the total brain to 
plasma concentration ratio  (Kp,brain) or brain-to-plasma 
AUC ratio of atenolol in rats and mice [54]. An in  situ 
intestinal perfusion study showed that verapamil, a Pgp 
inhibitor, did not change the absorption or intestinal 
permeability of atenolol [55, 56]. Similar conclusions 
that atenolol is not a Pgp substrate were drawn from 
in vitro studies using Caco-2 or Pgp transfected cell lines 
[40, 57]. On the other hand, Pgp inhibitors (cyclosporin 
and itraconazole) were reported to slightly increase the 
absorption rate and bioavailability of atenolol [58, 59]. 
However, these inhibitors are not specific and also act 
on other transporters. In addition, polarized transport 
of atenolol was found in a Pgp-transfected IPEC-J2 cell 
lines and Caco-2 cell with an efflux ratio of 3.5 and 2.3, 
respectively, which were decreased by addition of Pgp 
inhibitors (zosuquidar and verapamil) [60, 61]. In a col-
laborative study comparing Caco-2 cells from 10 labo-
ratories, atenolol showed highly variable permeability 
and its efflux ratios ranged from 0.18 to 3.76, indicating 
the possibility of an involvement of transporter-medi-
ated transport [38]. In summary, it is not clear which 
transporter(s) are responsible for the efflux of atenolol 
from brain, even though more solid evidence of trans-
porter involvement have been found related to the intes-
tinal absorption and renal secretion of atenolol.
Conclusions
The present study systematically evaluated the extent of 
S-atenolol distribution into and within the brain using 
microdialysis, and strongly suggests an involvement of 
carrier-mediated efflux of S-atenolol at the BBB, in addi-
tion to passive diffusion. Although it is currently unclear 
which transporter (or transporters) is responsible for 
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atenolol efflux transport at the BBB, it is likely not appro-
priate to use atenolol as a model drug for paracellular 
transport or passive diffusion. For any other candidate as 
a model drug of passive diffusion at the BBB, measure-
ment of  Kp,uu,brain based on unbound concentrations at 
steady state is useful to detect potential involvement of 
transporters in the BBB transport. The likely transport-
ers may have different expression levels and functions in 
other organs (e.g. intestine and kidney), thus the impor-
tance of carrier-mediated transport is likely different 
depending on the organ studied.
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